Previous 10 | Next 10 |
SILVER SPRING, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company ...
SILVER SPRING, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today the first pa...
SILVER SPRING, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plan...
Aziyo Biologics (AZYO) announces the completion of the product design for its CanGaroo, a biological envelope that forms a natural, systematically vascularized pocket for holding implantable electronic devices.The new product design includes the safety and performance of ...
SILVER SPRING, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today product desi...
Aziyo Biologics (AZYO) has received CE Mark approval for an updated labeling of its biological CanGaroo Envelope to allow for the addition of the antibiotic gentamicin.The Envelope is a small intestine submucosa extracellular matrix designed to mitigate complications deriving from implantable...
SILVER SPRING, Md., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it has receiv...
Surgalign ([[SRGA]] +1.5%) commences the commercial launch and the completion of the first surgery of ViBone Moldable, the newest orthobiologics solution of Surgalign’s bone graft portfolio to support spinal fusion, which currently include ViBone and other advanced bone graft...
DEERFIELD, Ill., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the application of digital technologies to improve patient outcomes, today announced the commercial launch and th...
Aziyo Biologics (AZYO): Q3 EPS of -$15.79 may not be comparable to consensus of -$2.37.Revenue of $11.77M (+5.7% Y/Y) beats by $0.56M.Press Release For further details see: Aziyo Biologics EPS of -$15.79
News, Short Squeeze, Breakout and More Instantly...
Aziyo Biologics Inc. Company Name:
AZYO Stock Symbol:
NASDAQ Market:
– Company to begin trading under new ticker symbol “ELUT” – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding ref...
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”...
Negotiating multiple LOIs to divest Orthopedic business CanGaroo ® RM 510(k) resubmission to the FDA remains on track SimpliDerm ® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular ...